Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 12, 2024, titled "Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)".
Press Release Jun 12 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
This approval allows Glenmark to distribute the product in the U.S. market, which is determined to be bioequivalent to a leading competitor's product. The company currently has a portfolio of numerous products authorized for distribution in the U.S. and continues to pursue additional approvals and partnerships.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Press Release May 24 2024
- Press Release May 21 2024
- Press Release May 17 2024
- Press Release Apr 29 2024
- Press Release Feb 14 2024
Later from Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Limited Press Release Jul 17 2024
- Press Release Aug 14 2024
- Glenmark Pharmaceuticals Limited Press Release Aug 19 2024
- Glenmark Pharmaceuticals Limited Press Release Nov 06 2024
- Press Release Nov 14 2024
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals